Treatment After Palbociclib-containing Regimens
To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.
Breast Cancer
PFS, Progression free survival, 6 weeks|Adverse events, Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0), 6 weeks
To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.